Painchek (ASX:PCK) ROE % Adjusted to Book Value: -56.47% (As of Dec. 2025)


What is Painchek ROE % Adjusted to Book Value?

Painchek ASX:PCK +4.17% ROE % Adjusted to Book Value is -56.47% as of Dec. 2025. The stock has 3 warning signs investors should review.

Painchek's ROE % for the quarter that ended in Dec. 2025 was -1,364.88%. Painchek's PB Ratio for the quarter that ended in Dec. 2025 was 24.17. Painchek's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 was -56.47%.

Painchek ROE % Adjusted to Book Value Related Terms

Painchek ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Painchek's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Painchek ROE % Adjusted to Book Value Chart

Painchek Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -12.19 -12.71 -5.60 -25.54 0.00

Painchek Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -16.98 -23.72 -15.69 0.00 -56.47

ASX:PCK vs VEEV, BTSG, TEM: ROE % Adjusted to Book Value Comparison

For the Health Information Services subindustry, Painchek's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Painchek ROE % Adjusted to Book Value vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Painchek's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Painchek's ROE % Adjusted to Book Value falls into.


Painchek ROE % Adjusted to Book Value Calculation

Painchek's ROE % Adjusted to Book Value for the fiscal year that ended in Jun. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-8,668.93% / N/A
=N/A

Painchek's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-1,364.88% / 24.17
=-56.47%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -56.47% mean?
Painchek (ASX:PCK) has a ROE % Adjusted to Book Value of -56.47% as of Dec. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Painchek and its competitors.
Is Painchek's ROE % Adjusted to Book Value too high?
Painchek's current ROE % Adjusted to Book Value is -56.47%.
How does Painchek's ROE % Adjusted to Book Value compare to VEEV and BTSG?
Painchek's ROE % Adjusted to Book Value of -56.47% can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Healthcare Providers & Services company?
A good ROE % Adjusted to Book Value depends on the Healthcare Providers & Services industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Painchek and its competitors. Painchek's current ROE % Adjusted to Book Value is -56.47%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Painchek stock overvalued right now?
Based on GuruFocus' analysis, Painchek (ASX:PCK) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.40, compared to a current price of A$0.10 — trading 75% below its estimated fair value. The current ROE % Adjusted to Book Value is -56.47%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Painchek (ASX:PCK), the current ROE % Adjusted to Book Value is -56.47% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Painchek Business Description

Address 35 Lime Street, Suite 401, Sydney, NSW, AUS, 2000
Painchek Ltd is engaged in the development and commercialization of mobile medical device applications that provide pain assessment for individuals who are unable to communicate pain with carers. It operates in one segment, namely the sale of its pain assessment solutions. Its geographic segments include Australia, the United Kingdom, and Other countries, of which it generates the majority of its revenue from Australia.